



**Written submission from
Gammatom s.r.l.**

**Mémoire de
Gammatom s.r.l.**

In the Matter of

À l'égard d'

Ontario Power Generation

Ontario Power Generation

Ontario Power Generation – Licence amendment application for the Darlington Nuclear Generating Station regarding the commercial production of Cobalt-60

Ontario Power Generation – Demande concernant la modification de son permis pour la centrale nucléaire de Darlington en vue de produire commercialement du Cobalt-60

Public Hearing – Hearing in writing based on written submissions

Audience publique – Audience fondée sur des mémoires

Spring 2024

Printemps 2024



gammatom s.r.l.

Phone Stabilimento di Guanzate
+39 031977379
+39 031976035
Fax +39 031976524
e-mail info@gammatom.it andrea.soldini@gammatom.it
web www.gammatom.it

To the Canadian Nuclear Safety Commission

8 March 2024

Ref Hearing Document: Application from Ontario Power Generation - Licence amendment for the Darlington Nuclear Generating Station regarding the commercial production of cobalt-60

Ref Hearing Notice Number: 2024-H-101

Ref Hearing Date: 24-04-22

Gammatom is an Italian enterprise, experiencing stable growth for over fifty years in both domestic and international markets. We specialize in gamma irradiation and sterilization services for healthcare, pharmaceutical, laboratory, veterinary and other scientific and industrial applications. We hold international certifications such as by the FDA and PMDA and national ones like AIFA and the Italian Ministry of Health.

Comments:

- The stable and ongoing availability of cobalt-60 is essential to our operation. We are not able to provide a reliable service to critical healthcare markets without the supply of cobalt-60. Over recent years we have seen that the availability of cobalt-60 has not been able to meet our needs.
- Since the COVID-19 pandemic, Italy has reinstated public health as a priority and healthcare is deemed a strategic asset. Therefore, the production of medical devices, health products and pharmaceuticals has expanded and operators such as Gammatom now have to make guarantees when undertaking public partnerships that are critical for the nation. The reliable availability of cobalt-60 is important when making such guarantees.
- The demand for irradiation and sterilization continues to increase every year. However, the supply of cobalt-60 is not growing at the same level. The gap between demand and supply is particularly of concern to our clients in the healthcare and pharmaceutical industries.

The availability of cobalt-60 from a small number of reactors has resulted in sterilization disruptions. This has an impact on the availability of healthcare products and the treatment of patients. This situation can be improved by increasing cobalt-60 production at existing and new reactors where the technology enables this.

Gammatom therefore supports a licence amendment that would enable commercial cobalt-60 production at OPG Darlington. This licence amendment would positively impact public health globally.

Yours sincerely,

gammatom srl

General Manager
Andrea Soldini

Sede operativa: Via XXIV Maggio, 14 - 22070 Guanzate (Como) - Tel. +39 031 977379 - 976035 - Fax. +39 031 976524 - 977413
Capitale € 10.400 Interamente Versato - Codice Fiscale e Partita IVA 03165630157

Sede Legale: Piazza Cavour, 3 - 20121 Milano - Iscritta al Tribunale di Milano Reg. Soc. n. 77363 - REA n. 411471

Codice Documento: (PQ-04) M.OFF Rev. 00
